Loading…
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $170M | $-255M | $-313M | $-179M | -61.5% | -25.1% | - |
| 2024 | $227M | $-484M | $-547M | $-382M | -76.4% | -9.7% | - |
| 2023 | $251M | $-822M | $-893M | $-336M | -81.4% | -47.4% | - |
| 2022 | $478M | $-2.1B | $-2.1B | $-304M | -121.2% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 477.71 | 251.46 | 227.04 | 170.16 |
| Cost Of Revenue | 204.22 | 54.01 | 44.55 | 46.97 |
| Gross Profit | 273.49 | 197.45 | 182.50 | 123.18 |
| Operating Expense | 2,482.44 | 965.65 | 670.22 | 427.06 |
| Operating Income | -2,208.95 | -768.20 | -487.73 | -303.88 |
| EBITDA | -2,078.74 | -822.34 | -484.39 | -254.61 |
| EBIT | -2,121.29 | -892.85 | -547.41 | -313.60 |
| Pretax Income | -2,121.40 | -892.94 | -547.51 | -313.60 |
| Tax Provision | -15.03 | -0.07 | -0.48 | -0.84 |
| Net Income | -2,104.93 | -892.87 | -547.03 | -312.76 |
| Net Income Common Stockholders | -2,104.93 | -892.87 | -547.03 | -312.76 |
| Total Expenses | 2,686.66 | 1,019.65 | 714.77 | 474.04 |
| Interest Expense | 0.11 | 0.09 | 0.09 | 0 |
| Interest Income | 20.26 | 57.22 | 38.61 | 22.62 |
| Research And Development | 1,052.64 | 580.62 | 424.06 | 243.77 |
| Selling General And Administration | 1,429.80 | 385.02 | 246.16 | 183.29 |
| Normalized EBITDA | -2,182.26 | -633.97 | -382.23 | -226.80 |
| Normalized Income | -2,207.72 | -704.51 | -444.96 | -285.04 |
| Basic EPS | -50 | -18.37 | -10.54 | -5.64 |
| Diluted EPS | -50 | -18.37 | -10.54 | -5.64 |
| Tax Effect Of Unusual Items | 0.73 | -0.01 | -0.10 | -0.08 |
| Tax Rate For Calcs | 0.01 | 0 | 0 | 0 |
| Total Unusual Items | 103.52 | -188.37 | -102.17 | -27.81 |
| Total Unusual Items Excluding Goodwill | 103.52 | -188.37 | -102.17 | -27.81 |
| Net Income From Continuing Operation Net Minority Interest | -2,104.93 | -892.87 | -547.03 | -312.76 |
| Reconciled Depreciation | 42.55 | 70.51 | 63.02 | 58.99 |
| Reconciled Cost Of Revenue | 204.22 | 54.01 | 44.55 | 46.97 |
| Net Interest Income | 20.16 | 57.12 | 38.52 | 22.62 |
| Net Income From Continuing And Discontinued Operation | -2,104.93 | -892.87 | -547.03 | -312.76 |
| Total Operating Income As Reported | -2,208.95 | -864.41 | -559.76 | -315.28 |
| Diluted Average Shares | 42 | 48.61 | 51.89 | 55.46 |
| Basic Average Shares | 41.98 | 48.61 | 51.89 | 55.46 |
| Diluted NI Availto Com Stockholders | -2,104.93 | -892.87 | -547.03 | -312.76 |
| Otherunder Preferred Stock Dividend | 3.14 | 0 | 0 | 0 |
| Minority Interests | 1.44 | 0 | 0 | 0 |
| Net Income Including Noncontrolling Interests | -2,106.37 | -892.87 | -547.03 | -312.76 |
| Net Income Continuous Operations | -2,106.37 | -892.87 | -547.03 | -312.76 |
| Other Income Expense | 67.40 | -181.87 | -98.30 | -32.34 |
| Other Non Operating Income Expenses | 7.63 | 9.14 | 3.87 | -4.53 |
| Special Income Charges | 31.89 | -138.71 | -79.04 | -11.40 |
| Gain On Sale Of Business | 31.89 | -42.50 | -7.01 | 0 |
| Other Special Charges | 0 | 0 | 0 | 0 |
| Impairment Of Capital Assets | 0 | 96.21 | 47.86 | 0 |
| Restructuring And Mergern Acquisition | 0 | 0 | 24.17 | 11.40 |
| Earnings From Equity Interest | -43.76 | -2.63 | 0 | 0 |
| Gain On Sale Of Security | 71.64 | -49.66 | -23.13 | -16.41 |
| Net Non Operating Interest Income Expense | 20.16 | 57.12 | 38.52 | 22.62 |
| Interest Expense Non Operating | 0.11 | 0.09 | 0.09 | 0 |
| Interest Income Non Operating | 20.26 | 57.22 | 38.61 | 22.62 |
| General And Administrative Expense | 1,429.80 | 385.02 | 246.16 | 183.29 |
| Other Gand A | 1,429.80 | 385.02 | 246.16 | 183.29 |
| Operating Revenue | 477.71 | 251.46 | 227.04 | 170.16 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Ginkgo Bioworks Holdings, Inc.this co. | DNA | $464M | - | 0.86 | -61.5% | -1.69 |
| Verastem, Inc. | VSTM | $474M | - | 7.34 | -366.2% | -2.10 |
| agilon health, inc. | AGL | $465M | - | 3.65 | -308.8% | -0.53 |
| Varex Imaging Corporation | VREX | $462M | - | 0.97 | -14.4% | 7.73 |
| Orthofix Medical Inc. | OFIX | $461M |
| - |
| 1.02 |
| -20.5% |
| -94.86 |
| 4D Molecular Therapeutics, Inc. | FDMT | $461M | - | 1.00 | -27.7% | -0.45 |
| MiMedx Group, Inc. | MDXG | $458M | 9.64 | 1.78 | 18.9% | 4.00 |
| Pacific Biosciences of California, Inc. | PACB | $456M | - | 81.67 | -10214.5% | -5.12 |
| Candel Therapeutics, Inc. | CADL | $453M | - | 6.53 | -73.5% | -8.07 |
| Peer Median | - | 9.64 | 2.72 | -50.6% | -1.32 | |